ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 159 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2018. The put-call ratio across all filers is 1.18 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2019 | $2,647,000 | +179.8% | 38,168 | +75.4% | 0.03% | +142.9% |
Q4 2018 | $946,000 | -72.1% | 21,765 | -50.9% | 0.01% | -67.4% |
Q3 2018 | $3,386,000 | -16.6% | 44,350 | -16.1% | 0.04% | -23.2% |
Q2 2018 | $4,061,000 | +28.5% | 52,834 | -14.8% | 0.06% | +14.3% |
Q1 2018 | $3,160,000 | -4.6% | 61,977 | -13.2% | 0.05% | +2.1% |
Q4 2017 | $3,313,000 | -19.9% | 71,440 | -8.0% | 0.05% | -18.6% |
Q3 2017 | $4,138,000 | -13.4% | 77,691 | +1.0% | 0.06% | -19.2% |
Q2 2017 | $4,778,000 | +20.1% | 76,927 | +31.1% | 0.07% | +9.0% |
Q1 2017 | $3,977,000 | +4.3% | 58,670 | +8.2% | 0.07% | -9.5% |
Q4 2016 | $3,813,000 | -28.8% | 54,225 | -28.2% | 0.07% | -21.3% |
Q3 2016 | $5,356,000 | +79.5% | 75,500 | +23.8% | 0.09% | +64.9% |
Q2 2016 | $2,984,000 | +17.9% | 61,000 | +52.5% | 0.06% | +16.3% |
Q1 2016 | $2,532,000 | -43.6% | 40,000 | 0.0% | 0.05% | -38.0% |
Q4 2015 | $4,487,000 | +16.5% | 40,000 | 0.0% | 0.08% | +21.5% |
Q3 2015 | $3,852,000 | – | 40,000 | – | 0.06% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |